Last updated: September 7, 2026
Levemir, Novo Nordisk’s insulin detemir, is in commercial decline. Its US product discontinuation was completed in 2024, and Novo Nordisk is withdrawing the product from additional markets because of declining demand, manufacturing constraints, and substitution by newer basal insulins. Levemir remains clinically established, but its financial relevance is falling rapidly as Tresiba, insulin glargine products, and lower-cost human insulins take share.
What is Levemir and how is it positioned in the basal insulin market?
Levemir is a long-acting recombinant insulin analog containing insulin detemir. Novo Nordisk received US approval in 2005 under NDA 021536 for once- or twice-daily treatment of diabetes mellitus [1].
The product uses fatty-acid acylation to promote reversible albumin binding. That mechanism produces a prolonged pharmacokinetic profile, although Levemir generally has a shorter duration of action than newer ultra-long-acting products in some patients.
| Attribute |
Levemir |
| Active ingredient |
Insulin detemir |
| Manufacturer |
Novo Nordisk |
| Therapeutic class |
Long-acting basal insulin analog |
| US approval |
2005 |
| US regulatory application |
NDA 021536 |
| Main dosage forms |
FlexPen, FlexTouch in certain markets, vials |
| Primary competitors |
Tresiba, Lantus, Toujeo, Basaglar, Semglee, NPH insulin |
| US commercial status |
Discontinued during 2024 |
| Global outlook |
Progressive withdrawal, with discontinuations extending through 2026 in some markets |
Levemir’s original differentiation was a flatter basal profile than NPH insulin and a lower risk of some weight-related effects than older insulin regimens. Its commercial position weakened as insulin glargine became widely available, biosimilar and follow-on glargine products entered the market, and Novo Nordisk shifted its basal-insulin strategy toward Tresiba.
When did Levemir lose market exclusivity?
Levemir’s primary composition and formulation protections have largely expired or ceased to provide a practical commercial barrier in the United States. The product’s current decline is driven more by market substitution and manufacturer withdrawal than by an imminent single generic launch.
Unlike small-molecule drugs, insulin products are regulated as biologics under the Biologics Price Competition and Innovation Act transition framework. The FDA moved insulin products from the drug framework into the biologics framework on March 23, 2020 [2].
This transition changed the competitive pathway:
- A new insulin detemir competitor would generally pursue a 351(k) biosimilar or interchangeable biosimilar pathway.
- A traditional Hatch-Waxman Paragraph IV challenge is not the normal legal route for a new insulin biologic.
- Patent disputes would generally arise through the biologics patent-exchange process, often called the “patent dance.”
- The Purple Book, rather than the Orange Book, is the primary FDA reference for licensed biologic products and biosimilar relationships.
What patents protect Levemir?
The original patent estate covered insulin detemir’s acylated insulin structure, production methods, and pharmaceutical formulations. Core protection has expired or reached the end of its practical commercial life in the United States.
The relevant protection categories include:
- Insulin detemir composition patents. These covered the modified insulin molecule and related acylated insulin analogs.
- Manufacturing patents. These covered recombinant production, purification, and chemical modification steps.
- Formulation patents. These addressed stabilized insulin solutions, excipients, concentration, and storage characteristics.
- Device and presentation patents. These covered pen injectors, cartridges, and delivery systems rather than the active ingredient itself.
The remaining patent risk is therefore more likely to concern manufacturing processes, formulation differences, or delivery devices than a broad, blocking patent on insulin detemir itself.
What is the Orange Book and Purple Book status of Levemir?
Levemir was originally approved through an FDA drug application, but insulin products became biologics subject to the transition provisions of the 2020 CARES Act framework. The regulatory analysis is consequently split between historical NDA records and current biologic regulation.
| Regulatory question |
Levemir status |
| FDA product application |
NDA 021536 |
| Current biologic framework |
351(a) reference-product framework after transition |
| Orange Book relevance |
Historical NDA record; not the principal biosimilar reference |
| Purple Book relevance |
Relevant biologic reference-product record |
| Approved interchangeable product |
None identified for insulin detemir as of the latest FDA listings |
| Safety-related withdrawal |
No |
| Commercial withdrawal |
Yes, based on demand and supply considerations |
Novo Nordisk’s withdrawal is not a regulatory safety action. FDA approval does not require a product to remain commercially available, and discontinuation does not by itself imply a change in the product’s benefit-risk profile.
How has Levemir revenue changed?
Levemir sales have declined materially over the past several years. Novo Nordisk’s annual reports show a sustained contraction in Levemir revenue as basal-insulin demand migrated to Tresiba, insulin glargine products, and lower-cost alternatives [3-6].
Publicly reported sales indicate the following broad trajectory:
| Period |
Levemir financial direction |
Main commercial driver |
| 2019-2020 |
High but declining sales base |
Mature basal-insulin franchise |
| 2021 |
Continued decline |
Tresiba adoption and glargine competition |
| 2022 |
Accelerated erosion |
Pricing pressure and formulary substitution |
| 2023 |
Sharp contraction |
US withdrawal planning and lower demand |
| 2024 |
Further decline |
US discontinuation and supply exits |
| 2025 onward |
Residual and declining sales |
Remaining international markets only |
Novo Nordisk’s reported Levemir revenue fell by more than 40% between the early 2020s and 2023, based on product sales disclosed in company annual reports. The absolute revenue loss is meaningful at the brand level but small relative to Novo Nordisk’s growth in GLP-1 products, including Ozempic, Rybelsus, and Wegovy.
What is Levemir’s revenue exposure for Novo Nordisk?
Levemir is no longer a major driver of Novo Nordisk’s enterprise value. Its decline affects:
- Basal-insulin portfolio revenue.
- Manufacturing utilization at insulin facilities.
- Sales-force and distribution economics.
- Patient retention within Novo Nordisk’s diabetes franchise.
- Revenue mix between mature insulin products and newer growth medicines.
The larger strategic issue is portfolio replacement. Novo Nordisk can lose Levemir sales while expanding total diabetes revenue if Tresiba, GLP-1 products, and obesity medicines continue to grow faster than Levemir declines.
When was Levemir discontinued in the United States?
Novo Nordisk announced a staged US discontinuation. Levemir FlexPen supply ended earlier in 2024, while vial availability continued into the end of the year. Novo Nordisk completed the US discontinuation by December 31, 2024, subject to remaining inventory and distribution conditions [7].
The principal stated factors were:
- Falling Levemir demand.
- Difficulties maintaining product supply.
- Lower manufacturing efficiency for a declining product.
- Availability of alternative basal insulins.
- A strategic shift toward Tresiba and other products.
The US withdrawal was commercially significant because the United States historically generated a disproportionate share of branded insulin revenue. It did not, however, eliminate global Levemir sales immediately.
Will Levemir be discontinued globally?
Novo Nordisk has indicated that Levemir discontinuations will extend beyond the United States, with some markets expected to lose the product by the end of 2026. The timing varies by country, formulation, regulatory requirements, inventory, and local reimbursement arrangements.
Global discontinuation creates several operational consequences:
- Physicians must transition patients to Tresiba, insulin glargine, NPH, or other basal-insulin regimens.
- Pharmacies must manage substitutions and inventory depletion.
- Health systems may face temporary increases in switching activity.
- Novo Nordisk loses a mature product but reduces complexity in manufacturing and distribution.
- Competitors gain an opportunity to capture insulin-detemir patients before they migrate to another Novo Nordisk product.
What generic and biosimilar entry risks exist for Levemir?
The immediate risk is not a classic generic launch. The more probable competitive pathways are biosimilar or follow-on insulin products and therapeutic substitution.
Biosimilar risk
No FDA-approved interchangeable insulin detemir biosimilar has been identified in the principal FDA biologic listings through the latest available regulatory data. The absence of an approved biosimilar does not eliminate future competition, but Levemir’s commercial withdrawal reduces the incentive to develop a direct copy.
A developer considering insulin detemir would face:
- A shrinking reference-product market.
- Limited opportunity to build a large US franchise.
- Manufacturing complexity associated with recombinant insulin.
- Need to establish biosimilarity under a 351(k) application.
- Potential competition from established insulin glargine products.
- Lower switching costs for prescribers and payers because basal-insulin alternatives are widely available.
Therapeutic substitution risk
The stronger commercial threat has been substitution by:
- Novo Nordisk’s Tresiba, or insulin degludec.
- Lantus and Toujeo, both insulin glargine products.
- Basaglar and Semglee.
- NPH insulin in price-sensitive channels.
- Human insulin products used under public and commercial formulary programs.
For Novo Nordisk, preserving the patient relationship through Tresiba conversion is commercially preferable to defending Levemir as a standalone brand.
What formulation and manufacturing IP barriers remain?
Levemir’s active ingredient is not technically simple to manufacture. A competitor must produce a consistent recombinant insulin analog, achieve acceptable purity, demonstrate stability, and meet stringent release specifications.
The principal manufacturing barriers include:
- Recombinant expression and folding.
- Chemical acylation of the insulin analog.
- Removal of process-related impurities.
- Control of aggregation and degradation.
- Sterility and preservative control.
- Device compatibility for pens and cartridges.
- Stability during temperature excursions.
- Demonstration of comparable pharmacokinetics and pharmacodynamics.
These barriers remain commercially relevant even after core composition patents expire. They are regulatory and operational barriers rather than durable exclusivity rights.
Formulation patents may still matter where a competitor seeks to copy a specific concentration, excipient system, or device presentation. A biosimilar applicant can often design around such claims by using a different formulation or presentation, subject to FDA comparability requirements.
Which companies are challenging or replacing Levemir?
No major active US Paragraph IV litigation campaign has defined the Levemir market. The competitive field is instead based on replacement products.
| Company |
Product |
Competitive role |
| Novo Nordisk |
Tresiba |
Primary internal replacement |
| Sanofi |
Lantus, Toujeo |
Leading glargine alternatives |
| Eli Lilly |
Basaglar |
Follow-on insulin glargine |
| Viatris/Biocon Biologics |
Semglee |
Biosimilar and interchangeable glargine competition |
| Various manufacturers |
NPH and human insulin |
Lower-cost substitution |
The absence of prominent Paragraph IV cases is consistent with Levemir’s biologic status and its shrinking commercial opportunity. A future biosimilar applicant would likely face patent and regulatory analysis under the BPCIA rather than a conventional small-molecule ANDA challenge.
What patent litigation and settlement agreements affect Levemir?
No major ongoing US patent litigation or public settlement agreement has materially changed Levemir’s current market outlook. The product’s commercial decline has been determined by discontinuation and substitution rather than by a court-imposed launch date.
Any future dispute would likely concern one of four areas:
- A biosimilar applicant’s manufacturing process.
- A formulation or concentration patent.
- A pen injector or cartridge design.
- Product labeling or method-of-use claims.
A direct insulin-detemir biosimilar launch would also require assessment of patent families in Europe, Canada, Japan, and other markets because the relevant expiration dates and enforcement practices differ by jurisdiction.
What is the competitive outlook for Levemir versus Tresiba?
Tresiba has the stronger long-term position within Novo Nordisk’s basal-insulin portfolio.
| Factor |
Levemir |
Tresiba |
| Active ingredient |
Insulin detemir |
Insulin degludec |
| Duration |
Long acting |
Ultra-long acting |
| Commercial lifecycle |
Mature and withdrawing |
Newer and actively commercialized |
| US availability |
Discontinued |
Available |
| Strategic role |
Legacy product |
Replacement basal insulin |
| Growth potential |
Minimal |
Higher, subject to pricing and competition |
| Manufacturing priority |
Reduced |
Higher |
Tresiba benefits from a longer duration of action and flexible dosing characteristics. Levemir retains clinical familiarity, but that advantage is insufficient to offset its withdrawal and weaker commercial momentum.
What generic launch scenarios exist for Levemir?
Three scenarios are commercially plausible:
Scenario 1: No direct biosimilar launch
This is the most likely scenario in the United States. Developers may prefer insulin glargine, where the addressable market is larger and biosimilar precedents are stronger.
Scenario 2: Limited regional insulin-detemir competition
A manufacturer could pursue insulin detemir in selected markets with lower development costs or public procurement opportunities. Such a product would likely compete on price rather than brand differentiation.
Scenario 3: Indirect replacement through basal-insulin switching
This scenario is already occurring. Patients move from Levemir to Tresiba, glargine, or NPH without a direct detemir competitor entering the market.
The third scenario has the greatest commercial effect because Levemir’s withdrawal creates a forced conversion event across multiple healthcare systems.
Key Takeaways
- Levemir is insulin detemir, a long-acting basal insulin analog approved by the FDA in 2005.
- Novo Nordisk completed the US commercial withdrawal during 2024.
- Additional international discontinuations are expected through 2026 in some markets.
- Levemir revenue has fallen sharply as Tresiba, insulin glargine products, and lower-cost insulins gained share.
- Core product protection no longer creates a meaningful US commercial barrier.
- A Paragraph IV generic challenge is not the primary competitive pathway because insulin is regulated as a biologic.
- No major FDA-approved interchangeable insulin-detemir biosimilar has been identified.
- The main replacement product is Novo Nordisk’s Tresiba.
- Levemir’s remaining value is concentrated in residual international sales, patient conversion opportunities, and manufacturing know-how rather than future standalone growth.
- Novo Nordisk’s enterprise-level financial exposure is limited because Levemir’s decline is being offset by growth in GLP-1 medicines and newer diabetes products.
FAQs About Levemir’s Market and Patent Outlook
Is Levemir still available in the United States?
No. Novo Nordisk discontinued US Levemir supply during 2024, with the full US withdrawal completed by the end of December 2024.
Is there a generic version of Levemir?
No widely available FDA-approved interchangeable insulin-detemir biosimilar has been identified. Patients are more commonly transitioned to Tresiba, insulin glargine, or NPH insulin.
Did Levemir lose exclusivity because of a Paragraph IV challenge?
No. Levemir’s decline was not driven by a major Paragraph IV launch event. Its competitive erosion resulted from patent maturation, therapeutic substitution, pricing pressure, and Novo Nordisk’s commercial discontinuation.
What insulin replaces Levemir after discontinuation?
Tresiba is Novo Nordisk’s principal replacement. Clinicians may also use Lantus, Toujeo, Basaglar, Semglee, NPH, or other basal-insulin regimens depending on clinical and reimbursement factors.
Is Levemir’s discontinuation related to a safety problem?
No. The withdrawal reflects commercial and supply considerations, including declining demand and manufacturing constraints, rather than a newly identified FDA safety action.
References
-
U.S. Food and Drug Administration. (2005). Levemir insulin detemir, NDA 021536: Prescribing information and approval history. FDA.
-
U.S. Food and Drug Administration. (2020). Regulatory transition of insulin and other products under the Biologics Price Competition and Innovation Act. FDA.
-
Novo Nordisk A/S. (2021). Annual report 2020. Novo Nordisk.
-
Novo Nordisk A/S. (2022). Annual report 2021. Novo Nordisk.
-
Novo Nordisk A/S. (2023). Annual report 2022. Novo Nordisk.
-
Novo Nordisk A/S. (2024). Annual report 2023. Novo Nordisk.
-
Novo Nordisk A/S. (2024). Levemir discontinuation and supply information for patients and healthcare professionals. Novo Nordisk.
